

Primary Sample Manual – Haematology
Issue No. 2.05 Effective Date: 18/04/19 Page 1 of 15
EUROFINS BIOMNIS

Written / Revised By: _____ **Date:** _____
Carol Wilson, Senior Medical Scientist

Reviewed By: _____ **Date:** _____
Dr. Patrick Hayden, Haematology Consultant

Authorised By: _____ **Date:** _____
Jean-Sébastien Charles, Quality Manager

Effective Date: 18/04/19 **Supersedes:** 2.04

File Type: Master **Assigned to:** Quality Department

Electronic copies are available to all staff on Q-Pulse and on the Eurofins Biomnis website.

The master copy is held in the Quality Department. Additional copies of this SOP must not be made without prior approval and documentation. Refer to SOP G94.

Issue No.	Revision Details	Effective Date
1.01	Addition of Malaria & D-dimer tests. Updated issue number format. Added reference to consultant. Issue number format updated.	25/10/2012
1.02	Update of DDimer preparation section.	14/12/2012
1.03	Update Accreditation for FBC & ADLC, Blood parasite. Addition of revision table.	25/02/2013
1.04	Updated TAT for Blood parasitology.	25/04/2013
1.05	Addition of reference range sources to all tests as per ISO15189:2012. Change of Accusay Malaria kit to OptiMAL kits.	08/04/2014
1.06	Coagulation updated from 4 hours stability to 12 hours as per revised WHO guidelines. D-dimer instrument updated to Roche Cobas h232 Point of Care meter.	23/04/15
1.07	Addition of Dr Patrick Hayden as haematology consultant Addition of Sat to running ESR Change of MS kit from Clearview IM (Inverness Medical) to Clearview IM II (Alere)	26/08/15
1.08	Removal of Blood Groups. Update for Blood parasitology stability. Change FBC stability from 3 days to 2 days.	19/04/17
2.01	Eurofins Biomnis rebranding	24/05/17
2.02	Minor discrepancy corrections	28/06/17
2.03	Activated partial thromboplastin time. Update transport & storage. Reference (SIEMENS Kit Insert & CSLI H21-A5). Update % parasitemia for Plasmodium knowlesi. Addition ideal procedure of avoidance of collecting blood through intravenous lines that have been previously flushed with heparin.	08/08/17
2.04	Travel history for parasitology & contact lab for symptomatic patients.	09/05/18

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

Issue No.	Revision Details	Effective Date
2.05	Addition of Reticulocyte test using XN1000. Addition of Sickledex Screening Kit. Change of Opti-Mal kit to CareStart Rapydtest malaria kit. Remove filaria & Trypanosomes from title - malaria only.	18/04/19

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

CONTENTS

FULL BLOOD COUNT (FBC).....	4
FULL BLOOD COUNT (FBC).....	5
ERYTHROCYTE SEDIMENTATION RATE (ESR).....	6
INFECTIOUS MONONUCLEOSIS.....	7
FIBRINOGEN (CLAUSS METHOD)	9
PROTHROMBIN TIME (PT).....	10
ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT).....	11
BLOOD PARASITOLOGY - MALARIA.....	12
D-DIMER	13
RETICULOCYTE.....	14
SICKLECELL SCREENING TEST	15

HAEMATOLOGY CONSULTANT RESPONSIBLE: Dr. Patrick Hayden
EUROFINS BIOMNIS: +353-1-295-8545

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

FULL BLOOD COUNT (FBC)

The Full Blood Count (FBC) is one of the most commonly requested laboratory tests and is a very useful indicator of potential problems that require further investigation. Common causes of an abnormal RCC & haematocrit include anaemia, acute blood loss & polycythaemia. Depressed WCC may be seen in AIDS, cancer and overwhelming infections. High WCCs are commonly observed in leukaemia and infections. A high neutrophil count often indicates an infection. A low lymphocyte count can be seen in AIDS patients. A high monocyte count can indicate a bacterial infection and a high eosinophil count indicates an allergic reaction or a parasitic infection. Common causes of a low platelet count include immune system disorders, some leukaemias and patients undergoing cancer treatments.

Preparation of patients: There is no physical preparation for the FBC test.

Precautions: Frozen, clotted, or grossly haemolysed samples can not be analysed.

Accredited	Yes						
Method	Haematology – Sysmex XE2100D SOP: H49						
Sample Requirements	Tube Type: Whole Blood EDTA (Lavender cap) Temperature: + 4°C Miscellaneous: Non fasting						
Turn Around Time – Setup Schedule	24h	Mon	Tue	Wed	Thu	Fri	Sat
		✓	✓	✓	✓	✓	✓
Stability	2 days @ + 4°C						
Units - Reference Ranges	Analyte	Adult Reference Range		Units Of Measurement			
		Male	Female				
	WBC	3.88-10.49	3.88-10.49	10 ⁹ /L			
	RBC	4.28-5.59	3.73-5.02	10 ¹² /L			
	HB	13.5-17.2	11.3-15.2	g/dL			
	HCT	0.381-0.499	0.323-0.462	Ratio			
	MCV	83.1-99.1	83.1-99.1	fL			
	MCH	28.3-33.9	28.3-33.9	pg			
	MCHC	32.1-36.6	32.1-36.6	g/dL			
	PLT	164-382	164-382	10 ⁹ /L			
	RDW	11.5-14.5	11.5-14.5	%			
	#Neut	1.56-6.52	1.56-6.52	10 ⁹ /L			
	#Lymph	1.01-3.13	1.01-3.13	10 ⁹ /L			
#Mono	0.23-0.88	0.23-0.88	10 ⁹ /L				
#Eos	0.05-0.51	0.05-0.51	10 ⁹ /L				
#Baso	0.02-0.15	0.02-0.15	10 ⁹ /L				

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

FULL BLOOD COUNT (FBC)

Source	<p>Reference ranges for FBC testing are derived from in house testing on corporate health screen clients (apparently healthy individuals).</p> <p>Data (n > 1000 all parameters, Male and Female subgroups n > 1000) was analysed according to the NCCLS C-28A guidelines, using the EP Evaluator software. Reference ranges were established using parametric, transformed parametric, or non-parametric methods as appropriate.</p> <p>Additionally, the in-house derived reference ranges are used in the moving-average calculations on the SYSMEX PC software. This is used to monitor instrument drift independent of patient population tested due to randomisation.</p>
---------------	---

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

ERYTHROCYTE SEDIMENTATION RATE (ESR)

The Erythrocyte Sedimentation Rate (ESR) is a traditional test used in Haematology. It is affected by the numbers of erythrocytes present in the blood, changes in plasma protein pattern, age and sex of the patient. Three phases can be distinguished in the sedimentation process: the lag phase (reflects the period in which the individual erythrocytes form rouleaux), the decantation or precipitation phase (the plasma-red cell interface falls more rapidly), and the final packing phase (the red cells aggregates pile up on the bottom of container). The ESR is dependent on the presence of agglomers, such as fibrinogen, IgM, alpha2-macroglobulin and other acute phase proteins. It is a completely non-specific test. It is a measure of the presence and severity of pathological processes. In general, the ESR is elevated in all acute, general infections, in localized, acute, inflammatory conditions, variations in the ESR depend on the nature and severity of the process. Additionally, the ESR is an important screen for occult disease. The ESR is also useful to differentiate organic disease from functional disorders, or as a guide to the progress of diseases such as rheumatic carditis, rheumatoid arthritis, and certain malignancies, including Hodgkin's disease, and is diagnostic for Temporal Arteritis.

Preparation of patients: There is no physical preparation for the ESR test.

Precautions: The ESR should not be used to screen healthy persons for disease.

Accredited	No						
Method	Haematology – Capillary photometric-kinetic technology SOP: H9						
Sample Requirements	Tube Type: Whole Blood (Lavender cap) Temperature: + 4°C Miscellaneous: Non fasting						
Turn Around Time – Setup Schedule	24h	Mon	Tue	Wed	Thu	Fri	Sat
		✓	✓	✓	✓	✓	✓
Stability	2 days @ + 4°C						
Units - Reference Ranges	mm/hr						
	ESR Ref Ranges	Male		Female			
	>50 Years	0-12		0-15			
	<50 Years	0-8		0-10			
Source	Reference ranges for the ESR assay are derived in house. Data was obtained from a clinical normal population and statistics generated using the Graph Pad statistics module. Data was analysed for Gaussian distribution and reference ranges derived using either parametric or non-parametric statistics. A copy of the data is kept in the QA department.						

**PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY**

INFECTIOUS MONONUCLEOSIS

Infectious mononucleosis (glandular fever) is an acute infectious disease caused by the Epstein-Barr virus and primarily affects lymphoid tissue. It is characterized by the appearance of enlarged and often tender lymph nodes, enlarged spleen, and abnormal lymphocytes in the blood. Patients usually, but not always, develop a transient heterophile antibody response.

The detection of heterophile antibodies of Infectious Mononucleosis by the agglutination of sheep red cells was first reported by Paul and Bunnell. Subsequent work identified the need for differential absorption of sera to remove non-infectious mononucleosis heterophile antibodies. Fetcher and Woolfolk showed that antigens obtained from bovine erythrocytes were more effective than those antigens obtained from either sheep or horse erythrocytes.

Preparation of patients: There is no physical preparation for the infectious mononucleosis test.

Precautions: IgG and IgM values obtained with different manufacturers' assay methods may not be used interchangeably. The magnitude of the reported IgG or IgM level cannot be correlated to an endpoint titre.

Accredited	No										
Method	Haematology- Immunoassay SOP: H20										
Sample Requirements	Tube Type: Whole blood serum or plasma Temperature: + 4°C Miscellaneous: Non fasting										
Turn Around Time – Setup Schedule	24h <table border="1" style="display: inline-table; vertical-align: middle;"> <thead> <tr> <th>Mon</th> <th>Tue</th> <th>Wed</th> <th>Thu</th> <th>Fri</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> </tr> </tbody> </table>	Mon	Tue	Wed	Thu	Fri	✓	✓	✓	✓	✓
Mon	Tue	Wed	Thu	Fri							
✓	✓	✓	✓	✓							
Stability	3 days @ + 4°C										
Result	Positive or negative										
Source	'Clearview IM II' Kit Insert, Alere group.										

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

SAMPLE REQUIREMENTS FOR COAGULATION TESTS

PROCEDURE

Sample Requirements and Collection

- Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase FVIII, vWF antigen and fibrinolysis. Venous occlusion should be avoided.
- Difficult venepuncture with trauma may lead to platelet activation with release of PF4 from alpha granules.
- Venous blood should be collected into coagulation tubes containing Sodium Citrate 3.2%, 0.105M, 3ml.
- Specimens must be mixed immediately post venepuncture to avoid clot activation, by GENTLY inverting the tubes 5 to 10 times.
- The ratio of whole blood to anticoagulant is crucial. Under-filled specimens will not be processed as over- or under-filled tubes can adversely affect results.
- Any warfarin treatment should be mentioned on the request form.

Transportation and Storage

- PT/INR specimens should ideally be analysed within 12 hours of collection and transported to the laboratory at room temperature.
- APTT and Fibrinogen should ideally be analysed within 4 hours of collection. Where this is not possible please centrifuge at room temperature (RT) @3000rpm (1500g) for at least 15 minutes, and then carefully remove the plasma from the cells, transfer to a fresh plastic plain tube and freeze at -20°C.
- Non-frozen coagulation specimens should be transported at RT ASAP to avoid deterioration of labile factors V and VIII.
- Collection of blood through intravenous lines that have been previously flushed with heparin should be avoided. In the event blood is drawn from an indwelling catheter, the line should be flushed with 5ml of saline, and the first 5ml of blood or 6 times the line volume be drawn off and discarded before coagulation tube is filled.

Plasma Sample Stability (CLSI H21-A5)

- PT 24 hours @ RT or 2 weeks @ -20°C
- APTT 4 hours @ RT or 2 weeks @ -20°C & 12 Months @ -70°C
- Fibrinogen- 4 hours @ RT

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

FIBRINOGEN (CLAUSS METHOD)

Clauss developed a simple method for the quantitative determination of Fibrinogen by measuring the clotting time of dilute plasma after the addition of Thrombin. The clotting time is inversely proportional to the Fibrinogen concentration. The clotting time obtained in this manner is then compared with that of a standardised Fibrinogen preparation. The plasma must be diluted to provide a low level of potential inhibitors, e.g. FDP's and Heparin. A strong Thrombin solution is utilised in order to ensure that the clotting time is independent of Thrombin concentration over a broad range.

Preparation of patient: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Venocclusion should be avoided.

Precautions: This test is not recommended for patients with active bleeding, acute infection or illness, or in those patients who have received blood transfusions within four weeks. Drugs that may increase Fibrinogen levels include Oestrogens and oral contraceptives. Drugs that may cause decreased levels include anabolic steroids, androgens, Phenobarbital, Urokinase, Streptokinase, and Valproic acid.

Accredited	Yes										
Method	Haematology- Coagulation SOP: H35										
Sample Requirements	Tube Type: Sodium Citrate Plasma (Light blue cap) Temperature: 4 hours Room temperature or 2 weeks @ -20°C. If an expected delay in transporting samples to the laboratory samples should be centrifuge, separated & send as frozen within 4 hours of blood collection. Miscellaneous: Non fasting Collection: Cf. Special requirement for Coagulation test										
Turn Around Time – Setup Schedule	24h <table border="1" style="margin-left: auto; margin-right: auto;"> <tr> <td>Mon</td> <td>Tue</td> <td>Wed</td> <td>Thu</td> <td>Fri</td> </tr> <tr> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> </tr> </table>	Mon	Tue	Wed	Thu	Fri	✓	✓	✓	✓	✓
Mon	Tue	Wed	Thu	Fri							
✓	✓	✓	✓	✓							
Stability	Reality: Within 4 hours, unless centrifuged at room temperature for 3000rpm (1500g) separated and frozen can only be thawed once. If an expected delay from collection time to receipt in the laboratory, suggest send frozen sample. (SIEMENS Kit Insert & CSLI H21-A5)										
Units - Reference Ranges	1.5-4.0 g/l										
Source	The RR was derived from the Adelaide & Meath Hospital CA-6000 Analyser. This is based on the correlation study during validation and compatible platforms, reagents, calibrators and controls.										

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

PROTHROMBIN TIME (PT)

The PT test (scientific name- tissue activated induced coagulation time) has been in clinical practice for over 60 years. The first standardised one-stage PT test was devolved by Dr. Armand Quick in 1932. It has now become the basic coagulation screening test for the diagnosis of acquired and congenital deficiencies of clotting factors in the Extrinsic pathway. The assay was designed to measure a coagulation defect before the introduction of oral anticoagulants, and later adapted for monitoring their dosage. The PT reflects changes in the Extrinsic factors II, VII and X, three of the principle clotting factors depressed by Coumarin drugs, and FV, not reduced by oral anticoagulation. It can also be used to assess the protein synthesis capability of the liver in chronic or acute hepatic disorders. The test depends on the activation of Factor X in the presence of Factor VII by Tissue Factor (TF) and bypassing of the Intrinsic clotting pathway. The speed of the reaction and the responsiveness of the PT to deficiencies of clotting factors depend upon the properties and concentration of the TF as well as on the clotting factor concentrations.

Preparation of patient: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Venocclusion should be avoided.

Precautions: The doctor should check to see if the patient is taking any medications that may affect test results. This precaution is particularly important if the patient is taking Warfarin, because there are a number of medications that can interact with Warfarin to increase or decrease the PT time.

Accredited	Yes										
Method	Haematology- Coagulation SOP: H33										
Sample Requirements	Tube Type: Sodium Citrate Plasma (Light blue cap) Temperature: 12 hours Room Temperature or 2 weeks @ -20°C Miscellaneous: Non fasting. Collection: Cf. Special requirement for Coagulation test										
Turn Around Time – Setup Schedule	24h <table border="1" style="margin-left: auto; margin-right: auto; text-align: center;"> <tr> <td>Mon</td> <td>Tue</td> <td>Wed</td> <td>Thu</td> <td>Fri</td> </tr> <tr> <td>✓</td> <td>✓</td> <td>✓</td> <td>✓</td> <td>✓</td> </tr> </table>	Mon	Tue	Wed	Thu	Fri	✓	✓	✓	✓	✓
Mon	Tue	Wed	Thu	Fri							
✓	✓	✓	✓	✓							
Stability	Whole blood: 12 hours at room temperature. If a longer delay is expected in transport to the laboratory, centrifuge @ 3000rpm (1500g) for at least 15 minutes, separate, and freeze plasma. Can only be thawed once. (SIEMENS Kit Insert & CSLI H21-A5)										
Units - Reference Ranges	PT 10 - 13 Seconds INR 0.9 - 1.3 INRW 2.0-4.0										
Source	The RR was derived from the Adelaide & Meath Hospital CA-6000 Analyser. This is based on the correlation study during validation and compatible platforms, reagents, calibrators and controls.										

**PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY**

ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT)

This test is also known as the Partial Thromboplastin Time with Kaolin (PTTK) and the Kaolin Cephalin Clotting Time (KCCT) reflecting the methods used to perform the test. The APTT is the main screening test for the Intrinsic clotting system and is the second most common coagulation test being exceeded in frequency only by the prothrombin time.

The Partial Thromboplastin of the APTT is a phospholipid extract of animal tissue or from vegetable sources. The phospholipids act as a platelet substitute in the Intrinsic system. The test incorporates an activator, in the absence of added Thromboplastin, which shortens the test and increases the precision and reproducibility by eliminating the variable effects of contact from glass surfaces and by effecting maximum activation. The activator is used to stimulate the production of FXIIa by providing a surface for the function of high molecular weight Kininogen, Kallikrein and FXIIa. The contact activation occurs for a time at 37°C. Calcium is then added to trigger further reactions and the time required for clot formation measured. Standardised Phospholipids are required to form complexes, which activate FX and Prothrombin, which allows the test to be conducted in patient Platelet poor plasma (PPP).

The test depends not only on the contact factors and factors VIII and IX, but also on the reactions with factors X, V, Prothrombin and Fibrinogen. It is also sensitive to the presence of circulating anticoagulants (inhibitors) and Heparin.

Preparation of patient: Patients should be relaxed pre-venepuncture. Excessive stress and exercise will increase Factor VIII, vWF antigen and fibrinolysis. Venocclusion should be avoided.

Precautions: APTT results may be affected by many commonly administered drugs and further studies should be made to determine the source of unexpected abnormal results. Oral contraceptive and Oestrogen therapy in males have been found to decrease APTT in vivo. Conversely, Heparin, Warfarin, Lupus anticoagulant and radio therapy have been found to increase APTT in vivo.

Accredited	Yes					
Method	Haematology – Coagulation SOP: H34					
Sample Requirements	Tube Type: Sodium Citrate Plasma (Light blue cap) Temperature: 4 hours Room temperature or 2 weeks -20°C Miscellaneous: Non fasting Collection: Cf. Special requirement for Coagulation test					
Turn Around Time – Setup Schedule	24h	Mon	Tue	Wed	Thu	Fri
		✓	✓	✓	✓	✓
Stability	Whole blood: 4 hours at room temperature. If a longer delay is expected in transport to the laboratory, centrifuge @ 3000rpm (1500g) for at least 15 minutes, separate, and freeze plasma. Can only be thawed once. (SIEMENS Kit Insert & CSLI H21-A5)					
Units - Reference Ranges	22.6-29.6 seconds.					
Source	The RR was derived from the Adelaide & Meath Hospital CA-6000 Analyser. This is based on the correlation study during validation and compatible platforms, reagents, calibrators and controls.					

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

BLOOD PARASITOLOGY - MALARIA

Malaria is caused by a group of related intracellular protozoan pathogens of the genus Plasmodium. These species exhibit a complex life cycle reliant on a mammalian host and anopheles mosquito vector. In the human host they are obligate intracellular pathogens infecting initially the liver in the sporozoite form. In the liver the parasites replicate and develop into merozoites which are then released into the blood stream. These infect the erythrocyte and begin a restricted life cycle. Each parasite may develop into a schizont (a cluster of infectious units which may invade further erythrocytes) or a gametocyte (the sexual form which may be transferred to the anopheles mosquito upon taking a blood meal). Re-infection of the liver does not occur.

Suspected malaria is a medical emergency. Sampling and processing of the blood sample must not be delayed if malaria is suspected. Five primary species of malaria have been identified in humans: *P.falciparum*, *P.vivax*, *P.ovale*, *P.malariae* and *P.knowlesi*. Their geographic distribution is unique for each species.

Blood should ideally be taken direct from the patient's finger or ear & the films prepared at the bedside or in the clinic. When this is not possible blood taken into anticoagulant (EDTA) can be used. Thick & thin blood films should be made as soon as possible, certainly less than 2 hours after the EDTA blood was drawn, to minimise morphological changes in the parasites. Parasite and red cell morphology can be seriously affected if the blood has been in anticoagulation for too long.

Where there is a strong clinical suspicion if the first films are negative, blood should be taken and films made and checked at least two times over the first 24 hours and further films examined every 12 hours after that if strongly clinically indicated.

Preparation of patients:

Travel history should be recorded and any clinical details recorded on the request form.

In symptomatic patients please phone the laboratory prior to sending the sample.

Precautions: Global distribution of malaria is restricted to areas endemic to the anopheles mosquito. Latent infections of some species may occur due to hypnozoites stored in the liver. *P. knowlesi* is morphologically indistinguishable from *P. malariae* on blood film preparations.

Accredited	Yes					
Method	Haematology – Thick & Thin Blood film & CareStart Malaria Rapydtest antigen kit (Kit Insert: APACOR CareStart ROPYDTEST- APA059 V7 04/2017) SOP: H47					
Sample Requirements	Tube Type: Whole Blood K2/K3 EDTA (Lavender cap) Thick & Thin blood films taken less than 2 hours after blood drawn. Temperature: + 4°C Miscellaneous: Non fasting Observe periodicity where applicable.					
Turn Around Time – Setup Schedule	24h	Mon	Tue	Wed	Thu	Fri
		✓	✓	✓	✓	✓
Stability	Blood films Thick & thin need to be made less than 2 hours after the blood EDTA was drawn. 2 days @ 2 - 8°C (CareStart ROPYDTEST Malaria Antigen Kit)					
Units - Reference Ranges	% parasitaemia (applicable to <i>P. falciparum</i> & <i>P. knowlesi</i> infection) No reference ranges applicable. Genus and species reportable.					
Source	WHO Guideline: 'The Laboratory Diagnosis of Malaria'. J.W Bailey, B.J Bain, J Parker-Williams and P.Chiodini for the General Haematology Task Force of the British Committee for Standards in Haematology. http://www.bcshguides.com/documents/malaria-bcsh.2005.pdf Malaria Reference Laboratory. www.malaria-reference.co.uk					

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

D-DIMER

D-dimer is a degradation product of cross-linked fibrin. The D-dimer concentration is a measure of the fibrinolytic activity of plasmin in the vascular system. Elevated concentrations of D-dimer indicate increased coagulatory and fibrinolytic activity. With a normal D-dimer value, acute deep vein thrombosis and pulmonary embolisms may be ruled out with high reliability.

Preparation of patients: There is no physical preparation for the D-Dimer test.

Precautions: No modifications to change diet, medications, or activity required before this test. Phlebotomists should enquire about any blood thinners or anticoagulant medication any diseases like liver disease and rheumatoid arthritis. There are some herbs that are also able to replicate the effects of blood thinning medication.

Accredited	No					
Method	Haematology – Roche Cobas h232 Point of Care meter SOP: H46					
Sample Requirements	Tube Type: Whole blood Lithium Heparin (green cap & Orange cap for Sarstedt tubes) Temperature: 15-25°C (Do not refrigerate or freeze) Miscellaneous: Non-fasting					
Turn Around Time – Setup Schedule	Same Day	Mon	Tue	Wed	Thu	Fri
		✓	✓	✓	✓	✓
Stability	8 hours @ 15-25°C					
Units - Reference Ranges	0.0-0.50 µg/mL					
Source	Roche Cardiac D-Dimer Assay Kit Insert – 2012-11, V4 English					

**PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY**

RETICULOCYTE

The process of red blood cell production starts in the bone marrow, where cells pass through various stages of development, becoming increasingly mature. The reticulocyte is the final stage of the development of the red blood cell before full maturation. Reticulocyte is an immature red blood cell without a nucleus, having a granular or reticulated appearance when suitably stained. They are present in normal blood in very low numbers, increased numbers are maybe the product of a pathological process or could be the body's response to pregnancy, therapy with iron B12, or folate or to blood loss. Reticulocytes are not part of the full blood count so they need to be specifically requested.

Preparation of patients: There is no physical preparation for the test.

Precautions: Frozen, clotted, or grossly haemolysed samples cannot be analysed.

Accredited	No						
Method	Haematology – SYSMEX XN1000 SOP: H56						
Sample Requirements	Tube Type: Whole Blood (Lavender cap) Temperature: + 4°C Miscellaneous: Non fasting						
Turn Around Time – Setup Schedule	24h	Mon	Tue	Wed	Thu	Fri	Sat
		✓	✓	✓	✓	✓	✓
Stability	2 days @ + 4°C						
Units - Reference Ranges	Reference Range for both Male & Female						
	Age	Absolute Reference Range			Age	% Reference Range	
	0 - 1 day	324 - 617 x10 ⁹ /L			0 - 1 day	1.72 - 8.62%	
	1 - 5 days	85 - 400 x10 ⁹ /L			1 - 5 days	1.9 - 9.1%	
	5 days - 1mth	34.2 - 724 x10 ⁹ /L			5 days - 1 mth	0.1 - 6.9%	
	1 - 3 mths	21.3 - 205 x10 ⁹ /L			1 - 3 mths	0.1 - 6.27%	
	3 - 12 mths	8.0 - 171 x10 ⁹ /L			3 - 12 mths	0.1 - 4.7%	
	1 - 3 yrs	55.6 - 120 x10 ⁹ /L			1 - 3 yrs	0.35 - 2.95%	
	3 - 7yrs	16.4 - 120.7 x10 ⁹ /L			3 - 7 yrs	0.25 - 2.57%	
	Adult	35.2 - 122.8 x10 ⁹ /L			Adult	0.75 - 2.7%	
Source	Haematology, G. Moore, G. Knight & A. Blann, 2 nd edition, Oxford 2016. The RR was derived from the Drogheda OLOL SYSMEX XN-1000 Analyser. The RR from OLOL Drogheda Our Ladys Hospital for Sick Children Crumlin, Great Ormond Street Hospital, Dacie & Lewis Practical Haematology 10th Edition and Pediatric Haematology 3rd Edition. This is based on the correlation study between OLOL hospital and Eurofins-Biomnis during validation and compatible platforms, reagents, calibrators and controls.						

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY

SICKLECELL SCREENING TEST

Sickle cell disease is an inherited condition characterised by the presence of Haemoglobin S (HB-S). Hb-S exists in a homozygous state (S/S) known as Sickle Cell Anaemia or in a heterozygous state (A/S) known as Sickle Cell Trait. Homozygous individuals (S/S) commonly exhibit symptoms of severe haemolytic anaemia and/or vascular occlusions. Heterozygous individuals (A/S) are usually asymptomatic. Hb-S may be present with other haemoglobins, such as Haemoglobin A, C or D, or with thalassemia, a condition that interferes with the synthesis of normal haemoglobin. Under conditions of low oxygen tension, the heterozygous (A/S) form can cause erythrocytes to form the characteristic sickle-shaped tactoids. The formation of these irreversible sickled red blood cells causes the onset of the acute symptoms. Detection of both the homozygous and heterozygous condition is important so high-risk individuals can be identified and their symptoms reduced.

SICKLEDEX® kit is a qualitative solubility test for testing the presence of sickling haemoglobins in human blood. Deoxygenated Hb-S is insoluble in the presence of a concentrated phosphate buffer solution and forms a turbid suspension that can be easily visualised. Normal Haemoglobin A and other haemoglobins remain in solution under these conditions. These different qualitative outcomes allow for the detection of sickle cell disease and its traits.

SICKLEDEX uses Saponin to lyse the red blood cells. Sodium Hydrosulfite then reduces the released haemoglobin. Reduced Hb-S is insoluble in the concentrated phosphate buffer and forms a cloudy turbid suspension. Other sickling haemoglobin subtypes may also give a positive result.

Preparation of patients: There is no physical preparation for the test.

Precautions: Frozen, clotted, or grossly haemolysed samples cannot be analysed.

Accredited	Yes										
Method	Haematology- qualitative solubility test for testing the presence of sickling haemoglobins SOP: H53										
Sample Requirements	Tube Type: Whole blood EDTA Temperature: + 4°C Miscellaneous: Non fasting										
Turn Around Time – Setup Schedule	24h <table border="1" style="display: inline-table; vertical-align: middle;"> <tr> <td>Mon</td> <td>Tue</td> <td>Wed</td> <td>Thu</td> <td>Fri</td> </tr> <tr> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> <td style="text-align: center;">✓</td> </tr> </table>	Mon	Tue	Wed	Thu	Fri	✓	✓	✓	✓	✓
Mon	Tue	Wed	Thu	Fri							
✓	✓	✓	✓	✓							
Stability	3 days @ + 4°C										
Result	Positive or negative										
Source	Sickledex kit insert, Streck – 350512-13, 05-2016.										

PRODUCTION OF UNAUTHORISED COPIES OF THIS SOP IS FORBIDDEN.
AUTHORISED COPIES ARE STAMPED IN GREEN – OFFICIAL COPY